ANTX (AN2 Therapeutics) Total Current Liabilities : $10.02 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is AN2 Therapeutics Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. AN2 Therapeutics's total current liabilities for the quarter that ended in Sep. 2024 was $10.02

AN2 Therapeutics Total Current Liabilities Historical Data

The historical data trend for AN2 Therapeutics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AN2 Therapeutics Total Current Liabilities Chart

AN2 Therapeutics Annual Data

Trend Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

1.46 3.40 7.19 14.04

AN2 Therapeutics Quarterly Data

Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24

Total Current Liabilities Get a 7-Day Free Trial 14.84 14.04 10.66 10.13 10.02

AN2 Therapeutics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

AN2 Therapeutics's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 9.357 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 4.686 + 0

= 14.04

AN2 Therapeutics's Total Current Liabilities for the quarter that ended in Sep. 2024 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 6.632 + 0

+ Other Current Liabilities + Current Deferred Liabilities

= 3.385 + 0

= 10.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

AN2 Therapeutics Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of AN2 Therapeutics's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

AN2 Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AN2 Therapeutics Inc (NAS:ANTX) » Definitions » Total Current Liabilities

Comparable Companies

COEP IBIO INTS IRD UBX CVKD PASG GDTC HSTC PULM VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270

Traded in Other Exchanges

N/A

Address

1800 El Camino Real, Suite D, Menlo Park, CA, USA, 94027

Website

https://www.an2therapeutics.com

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease.

Executives

Joshua M Eizen officer: See Remarks 3023 MONTBRETIA WAY, SAN RAMON CA 94582

Lucy Day officer: Chief Financial Officer 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301

Sanjay Chanda officer: Chief Development Officer C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303

Robin Shane Readnour director 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215

Joseph S Zakrzewski director 509 WATERVIEW PLACE, NEW HOPE PA 18938

Eric Easom director, officer: Chief Executive Officer 171 FOREST LN., MENLO PARK CA 94025

Ra Capital Healthcare Fund Lp 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Adjuvant Global Health Technology Fund De, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017

Kabeer Aziz director 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211

Kevin Michael Krause officer: Chief Strategy Officer 369 27TH STREET, SAN FRANCISCO CA 94131

Margaret M Fitzpatrick director C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080

Melvin K Spigelman director THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054

Ra Capital Nexus Fund Ii, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Adjuvant Global Health Technology Fund, L.p. 10 percent owner C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017

Michael Adrian Nazak officer: Chief Accounting Officer 5941 OPTICAL COURT, SAN JOSE CA 95138

AN2 Therapeutics Headlines

From GuruFocus

AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights
By Business Wire • 05-14-2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
By PRNewswire • 02-16-2024

AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights
By Business Wire • 11-09-2023

AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
By Business Wire • 08-10-2023

AN2 Therapeutics commences Phase 3 Part of Phase 2/3 Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium complex (MAC) Lung Disease
By Business Wire • 09-13-2023

AN2 Therapeutics Inc Chief Strategy Officer Kevin Krause Sells 7,417 Shares
By GuruFocus Research • 01-12-2024

AN2 Therapeutics Reports Third Quarter 2024 Financial Results, Provides Important EBO-301 Update and Highlights Progress Across Boron Chemistry Pipeline
By Business Wire • 11-13-2024

AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease
By Business Wire • 02-12-2024

AN2 Therapeutics to Present at JMP Securities Life Sciences Conference
By Business Wire Business Wire • 05-01-2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX
By PRNewswire • 02-24-2024

AN2 Therapeutics Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Liabilities	Get a 7-Day Free Trial											14.84	14.04	10.66	10.13	10.02

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	9.357	+	0
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	4.686	+	0
	=	14.04

Joshua M Eizen	officer: See Remarks	3023 MONTBRETIA WAY, SAN RAMON CA 94582
Lucy Day	officer: Chief Financial Officer	2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301
Sanjay Chanda	officer: Chief Development Officer	C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303
Robin Shane Readnour	director	3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215
Joseph S Zakrzewski	director	509 WATERVIEW PLACE, NEW HOPE PA 18938
Eric Easom	director, officer: Chief Executive Officer	171 FOREST LN., MENLO PARK CA 94025
Ra Capital Healthcare Fund Lp	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund De, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Kabeer Aziz	director	376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211
Kevin Michael Krause	officer: Chief Strategy Officer	369 27TH STREET, SAN FRANCISCO CA 94131
Margaret M Fitzpatrick	director	C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080
Melvin K Spigelman	director	THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054
Ra Capital Nexus Fund Ii, L.p.	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Adjuvant Global Health Technology Fund, L.p.	10 percent owner	C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Michael Adrian Nazak	officer: Chief Accounting Officer	5941 OPTICAL COURT, SAN JOSE CA 95138